SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $43.2 million in its second quarter.

On a per-share basis, the Salt Lake City-based company said it had a loss of 46 cents. Losses, adjusted for stock option expense and costs related to mergers and acquisitions, came to 25 cents per share.

The molecular diagnostic company posted revenue of $190.7 million in the period.

Myriad expects full-year revenue in the range of $770 million to $790 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN